Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Cut points identification of continuous biomarkers: A challenge that goes beyond statistical aspects.

Literature DB >> 34475238

Cut points identification of continuous biomarkers: A challenge that goes beyond statistical aspects.

Paulo Schiavom Duarte¹.
1. ICESP, Brazil.

Abstract

Entities: Chemical

Keywords: Biomarkers; Continuous; Cut points; Discretization; Research Methods; Statistical; Statistical Analysis; Statistics

Year: 2021 PMID： 34475238 PMCID： PMC8612177 DOI： 10.2967/jnumed.121.262905

Source DB: PubMed Journal: J Nucl Med ISSN： 0161-5505 Impact factor: 11.082

Keyword Cloud
References

× No keyword cloud information.

8 in total

Review 1. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework.

Authors:
Journal: Clin Pharmacol Ther Date: 2001-03 Impact factor: 6.875

2. A grey zone for quantitative diagnostic and screening tests.

Authors: Joël Coste; Jacques Pouchot
Journal: Int J Epidemiol Date: 2003-04 Impact factor: 7.196

3. Prediction of Time to Hormonal Treatment Failure in Metastatic Castration-Sensitive Prostate Cancer with ¹⁸F-FDG PET/CT.

Authors: Hossein Jadvar; Erik M Velez; Bhushan Desai; Lingyun Ji; Patrick M Colletti; David I Quinn
Journal: J Nucl Med Date: 2019-03-29 Impact factor: 10.057

4. Inflammation-Based Index and ⁶⁸Ga-DOTATOC PET-Derived Uptake and Volumetric Parameters Predict Outcome in Neuroendocrine Tumor Patients Treated with ⁹⁰Y-DOTATOC.

Authors: Elin Pauwels; Sofie Van Binnebeek; Vincent Vandecaveye; Kristof Baete; Hubert Vanbilloen; Michel Koole; Felix M Mottaghy; Karin Haustermans; Paul M Clement; Kristiaan Nackaerts; Eric Van Cutsem; Chris Verslype; Christophe M Deroose
Journal: J Nucl Med Date: 2019-12-05 Impact factor: 10.057

Cut points identification of continuous biomarkers: A challenge that goes beyond statistical aspects.

Review 1. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework.

2. A grey zone for quantitative diagnostic and screening tests.

3. Prediction of Time to Hormonal Treatment Failure in Metastatic Castration-Sensitive Prostate Cancer with ¹⁸F-FDG PET/CT.

4. Inflammation-Based Index and ⁶⁸Ga-DOTATOC PET-Derived Uptake and Volumetric Parameters Predict Outcome in Neuroendocrine Tumor Patients Treated with ⁹⁰Y-DOTATOC.

Review 5. Statistical Considerations in the Evaluation of Continuous Biomarkers.

6. Determining the optimal number and location of cutoff points with application to data of cervical cancer.

Review 7. Medical Diagnostic Tests: A Review of Test Anatomy, Phases, and Statistical Treatment of Data.

8. Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization.

Cut points identification of continuous biomarkers: A challenge that goes beyond statistical aspects.

Review 1. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework.

2. A grey zone for quantitative diagnostic and screening tests.

3. Prediction of Time to Hormonal Treatment Failure in Metastatic Castration-Sensitive Prostate Cancer with 18F-FDG PET/CT.

4. Inflammation-Based Index and 68Ga-DOTATOC PET-Derived Uptake and Volumetric Parameters Predict Outcome in Neuroendocrine Tumor Patients Treated with 90Y-DOTATOC.

Review 5. Statistical Considerations in the Evaluation of Continuous Biomarkers.

6. Determining the optimal number and location of cutoff points with application to data of cervical cancer.

Review 7. Medical Diagnostic Tests: A Review of Test Anatomy, Phases, and Statistical Treatment of Data.

8. Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization.

3. Prediction of Time to Hormonal Treatment Failure in Metastatic Castration-Sensitive Prostate Cancer with ¹⁸F-FDG PET/CT.

4. Inflammation-Based Index and ⁶⁸Ga-DOTATOC PET-Derived Uptake and Volumetric Parameters Predict Outcome in Neuroendocrine Tumor Patients Treated with ⁹⁰Y-DOTATOC.